SOHO State of the Art Updates and Next Questions | Early Intervention in Myelofibrosis: Where Are We and Does It Matter?
Clin Lymphoma Myeloma Leuk. 2024 Mar 6:S2152-2650(24)00093-4. doi: 10.1016/j.clml.2024.02.015. Online ahead of print.ABSTRACTHistorically, therapeutic clinical trials in myelofibrosis have predominantly focused on targeting patients with higher-risk disease who are at risk of increased morbidity and mortality. The endpoints have been designed to target regularly measured disease parameters that are of immediate pertinence to patient's welfare including splenic volume reduction and symptom reduction. These efforts have resulted in meaningful and measurable improvements in disease parameters in these high-risk study populati...
Source: Clinical Lymphoma and Myeloma - March 29, 2024 Category: Cancer & Oncology Authors: Abdulraheem Yacoub Nicole Twardowski Alec Britt Nour Shraim Source Type: research
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes
CONCLUSION: TN-MF is invariably associated with significantly decreased survival and more aggressive clinical behavior with higher rates of leukemic transformation and shorter duration of response to ruxolitinib. Mutations impacting RNA splicing, epigenetic modification and signaling (SRSF2, SETBP1, IDH2, CBL, and GNAS) are more common in TN-MF, which likely drive its aggressive course and may account for suboptimal responses to JAK inhibition.PMID:38548563 | DOI:10.1016/j.clml.2024.03.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 28, 2024 Category: Cancer & Oncology Authors: Luis E Aguirre Akriti Jain Somedeb Ball Najla Al Ali Virginia O Volpe Sara Tinsley-Vance David Sallman Kendra Sweet Jeffrey Lancet Eric Padron Seongseok Yun Andrew Kuykendall Rami Komrokji Source Type: research
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes
CONCLUSION: TN-MF is invariably associated with significantly decreased survival and more aggressive clinical behavior with higher rates of leukemic transformation and shorter duration of response to ruxolitinib. Mutations impacting RNA splicing, epigenetic modification and signaling (SRSF2, SETBP1, IDH2, CBL, and GNAS) are more common in TN-MF, which likely drive its aggressive course and may account for suboptimal responses to JAK inhibition.PMID:38548563 | DOI:10.1016/j.clml.2024.03.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 28, 2024 Category: Cancer & Oncology Authors: Luis E Aguirre Akriti Jain Somedeb Ball Najla Al Ali Virginia O Volpe Sara Tinsley-Vance David Sallman Kendra Sweet Jeffrey Lancet Eric Padron Seongseok Yun Andrew Kuykendall Rami Komrokji Source Type: research
SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia
We present our approach to newly diagnosed patients with B-ALL and illustrate how the incorporation of novel agents and use of high-sensitivity MRD assays can abrogate the need for allo-SCT in most patients with B-ALL.PMID:38538495 | DOI:10.1016/j.clml.2024.02.017 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 27, 2024 Category: Cancer & Oncology Authors: Wei-Ying Jen Elias Jabbour Hagop M Kantarjian Nicholas J Short Source Type: research
Are the GLIM Criteria Guiding in the Course of Hematological Malignancies?
CONCLUSION: Early nutritional support can increase the immunological status of patients with malignant disorders as well as their tolerability to treatment. Minimizing the risk of malnutrition and providing timely calorie and vitamin support are factors that may directly affect febrile neutropenia, duration of fever, and antifungal use, which will consequently lead to a decrease in the length of hospitalization.PMID:38528354 | DOI:10.4103/njcp.njcp_572_23 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 26, 2024 Category: Cancer & Oncology Authors: F Yilmaz M R Aras Hba Ozturk H N Sahin A K Gunes M Albayrak Source Type: research
Are the GLIM Criteria Guiding in the Course of Hematological Malignancies?
CONCLUSION: Early nutritional support can increase the immunological status of patients with malignant disorders as well as their tolerability to treatment. Minimizing the risk of malnutrition and providing timely calorie and vitamin support are factors that may directly affect febrile neutropenia, duration of fever, and antifungal use, which will consequently lead to a decrease in the length of hospitalization.PMID:38528354 | DOI:10.4103/njcp.njcp_572_23 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 26, 2024 Category: Cancer & Oncology Authors: F Yilmaz M R Aras Hba Ozturk H N Sahin A K Gunes M Albayrak Source Type: research
Are the GLIM Criteria Guiding in the Course of Hematological Malignancies?
CONCLUSION: Early nutritional support can increase the immunological status of patients with malignant disorders as well as their tolerability to treatment. Minimizing the risk of malnutrition and providing timely calorie and vitamin support are factors that may directly affect febrile neutropenia, duration of fever, and antifungal use, which will consequently lead to a decrease in the length of hospitalization.PMID:38528354 | DOI:10.4103/njcp.njcp_572_23 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 26, 2024 Category: Cancer & Oncology Authors: F Yilmaz M R Aras Hba Ozturk H N Sahin A K Gunes M Albayrak Source Type: research
Dampening Logistics Creating Inequitable Access: A Major Threat Despite Advancements
Clin Lymphoma Myeloma Leuk. 2024 Feb 22:S2152-2650(24)00083-1. doi: 10.1016/j.clml.2024.02.011. Online ahead of print.NO ABSTRACTPMID:38521639 | DOI:10.1016/j.clml.2024.02.011 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 23, 2024 Category: Cancer & Oncology Authors: Fathima Shehnaz Ayoobkhan Al-Ola Abdallah Faiz Anwer Nausheen Ahmed Source Type: research
Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma
CONCLUSIONS: In our large study, monetary status but not disease status predicted FinTox. Over a third of patients on maintenance reported TimeTox. FinTox+ was associated with decreased mental health, while TimeTox+ was associated with worse performance status. These two toxicities may negatively impact patient wellbeing, and studies of strategies to mitigate their impact are in development.PMID:38521640 | DOI:10.1016/j.clml.2024.02.013 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 23, 2024 Category: Cancer & Oncology Authors: Rahul Banerjee Andrew J Cowan Marivel Ortega Constance Missimer Paul A Carpenter Masumi Ueda Oshima Rachel B Salit Phuong T Vo Catherine J Lee Rohtesh S Mehta Nicole M Kuderer Veena Shankaran Stephanie J Lee Christopher T Su Source Type: research
Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2024 Feb 12:S2152-2650(24)00063-6. doi: 10.1016/j.clml.2024.02.004. Online ahead of print.ABSTRACTIsatuximab-based combinations are among the accepted standard-of-care regimens for early-line treatment of patients with relapsed/refractory multiple myeloma (RRMM), based on the results of the Phase 3 ICARIA-MM and IKEMA trials. Further study findings have shown benefit with Isa-based combinations in patients with newly diagnosed MM, as reported from the randomized GMMG-HD7 and CONCEPT trials. Isa is currently approved in various countries for intravenous (IV) administration in patients with RRMM. ...
Source: Clinical Lymphoma and Myeloma - March 22, 2024 Category: Cancer & Oncology Authors: Hang Quach Gurdeep Parmar Maria-Victoria Mateos Sikander Ailawadhi Xavier Leleu Source Type: research
Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma
Clin Lymphoma Myeloma Leuk. 2024 Feb 12:S2152-2650(24)00063-6. doi: 10.1016/j.clml.2024.02.004. Online ahead of print.ABSTRACTIsatuximab-based combinations are among the accepted standard-of-care regimens for early-line treatment of patients with relapsed/refractory multiple myeloma (RRMM), based on the results of the Phase 3 ICARIA-MM and IKEMA trials. Further study findings have shown benefit with Isa-based combinations in patients with newly diagnosed MM, as reported from the randomized GMMG-HD7 and CONCEPT trials. Isa is currently approved in various countries for intravenous (IV) administration in patients with RRMM. ...
Source: Clinical Lymphoma and Myeloma - March 22, 2024 Category: Cancer & Oncology Authors: Hang Quach Gurdeep Parmar Maria-Victoria Mateos Sikander Ailawadhi Xavier Leleu Source Type: research
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis
CONCLUSION: The combination of ofatumumab, HDMP, and lenalidomide was effective and relatively well tolerated in treatment-naive CLL/SLL. Its role in the frontline setting remains unclear given the current available and effective treatment options.FUNDING: The funders had no role in the study.PMID:38508880 | DOI:10.1016/j.clml.2024.02.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 20, 2024 Category: Cancer & Oncology Authors: Julio C Chavez Ariel Grajales Jose Sandoval-Sus Elyce Turba Lisa Nodzon Angimar Uriepero-Palma Mohammad Ammad-Ud-Din Eva Sahakian Rami Komrokji Lubomir Sokol Frederick L Locke Bijal Shah Jeffrey Lancet Eduardo M Sotomayor Mohamed A Kharfan-Dabaja Celeste Source Type: research
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis
CONCLUSION: The combination of ofatumumab, HDMP, and lenalidomide was effective and relatively well tolerated in treatment-naive CLL/SLL. Its role in the frontline setting remains unclear given the current available and effective treatment options.FUNDING: The funders had no role in the study.PMID:38508880 | DOI:10.1016/j.clml.2024.02.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 20, 2024 Category: Cancer & Oncology Authors: Julio C Chavez Ariel Grajales Jose Sandoval-Sus Elyce Turba Lisa Nodzon Angimar Uriepero-Palma Mohammad Ammad-Ud-Din Eva Sahakian Rami Komrokji Lubomir Sokol Frederick L Locke Bijal Shah Jeffrey Lancet Eduardo M Sotomayor Mohamed A Kharfan-Dabaja Celeste Source Type: research
Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib
Clin Lymphoma Myeloma Leuk. 2024 Feb 29:S2152-2650(24)00092-2. doi: 10.1016/j.clml.2024.02.014. Online ahead of print.NO ABSTRACTPMID:38503634 | DOI:10.1016/j.clml.2024.02.014 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 19, 2024 Category: Cancer & Oncology Authors: Fadi G Haddad Cedric Nasnas Koji Sasaki Shilpa Paul Ghayas C Issa Caitlin Rausch Elias Jabbour Hagop Kantarjian Source Type: research
Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib
Clin Lymphoma Myeloma Leuk. 2024 Feb 29:S2152-2650(24)00092-2. doi: 10.1016/j.clml.2024.02.014. Online ahead of print.NO ABSTRACTPMID:38503634 | DOI:10.1016/j.clml.2024.02.014 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 19, 2024 Category: Cancer & Oncology Authors: Fadi G Haddad Cedric Nasnas Koji Sasaki Shilpa Paul Ghayas C Issa Caitlin Rausch Elias Jabbour Hagop Kantarjian Source Type: research
